Article
Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2008
de Snoo Femke A, Bishop D Timothy, Bergman Wilma, van Leeuwen Inge, van der Drift Clasine, van Nieuwpoort Frans A, Out-Luiting Coby J, Vasen Hans F, ter Huurne Jeanet A C, Frants Rune R, Willemze Rein, Breuning Martijn H, Gruis Nelleke A
Abstract excerpt
PURPOSE: We report the largest study to date analyzing the risk of cancers other than melanoma in melanoma families positive for the same CDKN2A mutation. EXPERIMENTAL DESIGN: We studied family members of 22 families positive for the p16-Leiden founder mutation who had attended a surveillance clinic or were their close relatives. Within this cohort, observed and expected rates of cancer were computed by mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.